Abstract SIB1 FKBP22 is a peptidyl prolyl cis-trans isomerase (PPIase) member from a psychrotrophic bacterium, Shewanella sp. SIB1, consisting of N-and C-domains responsible for dimerization and catalytic PPIase activity, respectively. This protein was assumed to be involved in cold adaptation of SIB1 cells through its dual activity of PPIase activity and chaperone likefunction. Nevertheless, the catalytic inhibition by FK506 and its substrate specificity remain unknown. Besides, ability of SIB1 FKBP22 to inhibit phosphatase activity of calcinuerin is also interesting to be studied since it may reflect wider cellular functions of SIB1 FKBP22. In this study, we found that wild type (WT) SIB1 FKBP22 bound to FK506 with IC 50 of 77.55 nM. This value is comparable to that of monomeric mutants (NNC-FKBP22, C-domain+ and V37R/L41R mutants), yet significantly higher than that of active site mutant (R142A). In addition, WT SIB1 FKBP22 and monomeric variants were found to prefer hydrophobic residues preceding proline. Meanwhile, R142A mutant has wider preferences on bulkier hydrophobic residues due to increasing hydrophobicity and binding pocket space. Surprisingly, in the absence of FK506, SIB1 FKBP22 and its variants inhibited, with the exception of N-domain, calcineurin phosphatase activity, albeit low. The inhibition of SIB1 FKBP22 by FK506 is dramatically increased in the presence of FK506. Altogether, we proposed that local structure at substrate binding pocket of C-domain plays crucial role for the binding of FK506 and peptide substrate preferences. In addition, C-domain is essential for inhibition, while dimerization state is important for optimum inhibition through efficient binding to calcineurin.
Introduction
The trans conformation is preferred overwhelmingly in most peptide bonds of fully folded proteins. By contrast, prolyl bond, a peptide bond preceding proline residue, often found to be in cis conformation in the folded state [1] [2] [3] . Trans conformation is energetically more favorable since steric hindrance between the functional group attached to Cα is less in this conformation [3] . However, steric hindrance is not an issue in proline due to a cyclic structure of proline side chain yielding the equivalent energy between cis and trans conformation and conformational freedom [2] . Consequently, isomerization of cis-trans prolyl bond occurs yet at very slow rate. For cis-proline containing proteins, Ribonuclease T1 and the N-terminal domain of the gene-3 protein of the filamentous phage fd, to name a few, this isomerization is considered as a limited step of the folding rate [3] . The kinetic of the cis-trans interconversion is intrinsically slow because it involves the rotation about a partial double bond, therefore, prolyl isomerization can retard protein folding by 1000-fold or more [3] . Given fast folding rate is very important for protein to achieve correct fold, enhancing cis-trans prolyl bond isomerization rate is needed.
Peptidyl prolyl cis-trans isomerase (PPIase, EC 5.2.1.8) is a group of enzyme capable of catalyzing the rate of cis-trans prolyl bond isomerization. The detail mechanism by which PPIase catalyzes the isomerization remains an open question, yet it is believed through reduction of rotational barrier through disruption of the partial double bond character of the peptide bond [2, 4] . This enzyme is classified into three unrelated family member, FK506-binding protein (FKBP), cyclophilin (Cyp) and parvulin (Par), with high conservation of amino acids in the same family but limited similarity among different families [5] .
We previously had identified a member of FKBP family protein from a psychrotrophic bacterium, Shewanella sp. SIB1, namely SIB1 FKBP22 [6, 7] . This protein was proposed to be involved in cold adaptation of the cell by accelerating folding rate of cis-proline containing proteins that extremely slow at low temperature [7] . This protein assumes a V-shaped dimeric structure consisting of N-and C-domains, responsible for dimerization and PPIase activity, respectively. Apart from its PPIase activity, SIB1 FKBP22 also exhibited chaperone-like activity as demonstrated by its ability to bind to a folding intermediate protein and prevent protein aggregation [7] [8] [9] .
It has been previously reported that when the dimeric structure of SIB1 FKBP22 is disrupted, only chaperonelike activity was seriously affected. In addition, monomeric variants, with the presence of C-domain, retained its PPIase activity [7, 10, 11] . However, it is interesting to be noted that catalytic efficiency (k cat /K M ) of SIB1 FKBP22 in monomeric form is slightly higher than in dimeric structure [10, 11] . We previously speculated that this is due to the restriction of flexibility and freedom of catalytic domain to bind to the ligand by the dimeric structure. However, no experimental evidences have so far been reported to confirm this speculation.
FK506 or tacrolimus is known to be a specific ligand for FKBP family members [12] . In the cell, a complex of FKBP12 and FK506 has been known to interact to a calcium and calmodulin dependent serine/threonine protein phosphatase (calcineurin). The interaction further promoted inhibition of phosphatase activity leading to disruption of phosphate-mediated signal transduction. Consequently, ability of FKBP to bind to FK506 is associated with the cellular function of this protein [13] . The binding property of SIB1 FKBP22 towards FK506 and its inhibition to calcineurin, yet, is unknown. Besides, it is also unknown if SIB1 FKBP22 has substrate specificity as other FKBPs members, in which hydrophobic residues preceding proline is more favorable for catalysis [5] . On top of that, how does dimeric structure regulate the ligand binding and substrate specificity in FKBP family member remain to be investigated.
In this study, inhibition of catalytic activity of SIB1 FKBP22 by FK506, substrate specificity, and ability of SIB1 FKBP22-FK506 complex to inhibit phosphatase activity of calcineurin were examined by using dimeric form of WT SIB1 FKBP22, monomeric variants (NNC-FKBP22, C-domain+, V37R/L41R mutants), active site dimeric mutant (R142A) and N-domain. We found that SIB1 FKBP22 indeed bound to and was catalytically inhibited by FK506. The binary of SIB1 FKBP22 and FK506 was also able to inhibit phosphatase activity of calcineurin. We also demonstrated that SIB1 FKBP22 highly prefer bulky hydrophobic residues preceding prolyl bond. Further, we discuss the effect of dimerization and mutation at substrate binding pocket structure on these events.
Materials and Methods

Protein Preparation
All proteins were prepared in a His-tagged form. Plasmid pWT-FKBP22, pNNC-FKBP22, pVL-FKBP22, pCD-FKBP22 and pR142A were constructed and used to overproduce full length SIB1 FKBP22, NNC-FKBP22, V37R/ L41R-FKBP22, N-domain and R142A mutant as previously described [9, 11, 14] . The plasmids were then transformed into Escherichia coli strain BL21(DE3) for overproduction purpose.
Overproduction and purification of the proteins were carried out as described previously for SIB1 FKBP22 [6, 11] . Production levels of the recombinant proteins in E. coli cells and the purities was analyzed by SDS-PAGE using 15% polyacrylamide gel, followed by staining with Coomassie Brilliant Blue R250 [15] . Protein concentrations of SIB1 FKBP22 and its derivatives were determined using UV absorption on the basis that the absorbance at 280 nm of a 0.1% (1 mg mL −1 ) solution is 0.68 for SIB1-FKBP22, R142A-FKBP22 and V37R/L41R-FKBP22, and 0.61 for NNC-FKBP22. These values were calculated by using ε = 1576 M −1 cm −1 for Tyr and 5225 M −1 cm −1 for Trp at 280 nm [16] . For N-domain+, which contains only one tyrosine residue and no tryptophan residues, a method of Scopes [17] was used to confirm the accuracy of its concentration. In this method, the protein concentration (mg mL 
Catalytic Inhibition by FK506
The inhibition of PPIase activity of SIB1 FKBP22 and its variants by FK506 was determined by measuring PPIase activity in the presence of various concentration of FK506. The PPIase activity was determined in 35 mM HEPES buffer, pH 7.8, at 10 °C in the protease-coupled assay using N-succinyl-Ala-Leu-Pro-Phe-p-nitroanilide (Suc-ALPFpNA) (Wako Pure Chemical, Osaka Japan) at 25 µM of final concentration [6, 11] . FK506 stock (Sigma-Aldrich, St. Louis, MO), was prepared in 50% ethanol. The cocktail of substrate and FKBP22 was incubated with various concentration of FK506 for 5 min prior at 10 °C to the addition 1 3 of chymotrypsin to begin the reaction. In the presence of chymotrypsin, pNA moety is released from the substrate within a few seconds when the peptide bond N-terminal of the proline residue in the substrate assumes the trans conformation. However, pNA is not released from the substrate when this peptide bond is in the cis conformation. Isomerization rate was therefore measured by monitoring the change in the concentration of pNA under a Hitachi U-2010 UV/ VIS spectrophotometer (Hitachi High-Technologies Co., Tokyo, Japan) at 390 nm on the basis of the molar absorption coefficient value of 8900 m −1 cm −1 . The increase in the rate of isomerization is implicit in the increased rate of pNA release, because catalysis of isomerization produces trans substrate with increased frequency [6] . The catalytic efficiency (k cat ⁄K M ) was calculated from the relationship k cat /K M = (kp − kn)/E, where E represents the concentration of the enzyme, and kp and kn represent the first-order rate constants for the release of pNA from the substrate in the presence and absence of the enzyme, respectively [18] . To calculate IC 50 value, a curve was constructed by plotting k cat ⁄K M , expressed as relative value to the control, versus FK506 concentration. It was then fitted with the equation for IC 50 value in SigmaPlot 10.1 (Systat Software Inc., Chicago, IL, USA). The reaction in the absence of FK506 was treated as control.
Calcineurin Inhibition Assay
The assay was performed following [19] that measured phosphatase activity of 40 nM bovine brain calcineurin (SigmaAldrich, St. Louis, MO) in the presence or absence of SIB1 FKBP22 or its variants. For the measurement, the ProFluor serine/threonine phosphatase assay (Promega, Madison, USA) was used, which works based on the fluorescence of a rhodamine-conjugated peptide substrate that, upon dephosphorylation by calcineurin, is digested by a protease. All reactions were made in 100 µl volume as according to the manufacturer's instructions and supplemented with calmodulin (Sigma-Aldrich, St. Louis, MO). Meanwhile, reactions that include recombinant SIB1 FKBP22 or its variants alone or drug alone, 5 µl of 20 µM stock solution was added (final concentration of 1 µM); for reactions that included both recombinant protein and drug, 2.5 µl of 40 µM stock solutions was used (final concentration of 1 µM for both). Fluorescence was monitored using a The Agilent Cary Eclipse Fluorescence Spectrophotometer.
Substrate Specificity
Substrate specificity was measured by measuring PPIase activity as explained above with N-succinyl-Ala-Xaa-ProPhe-p-nitroanilide (Suc-AXaaPF-pNA) (Wako Pure Chemical, Osaka, Japan) as a substrate, in which Xaa stands for a variable aminoacyl residue in the P1 position of various substrates, in the absence of FK506. The catalytic efficiency obtained from Suc-AFPF-pNA was adjusted to 100% activity according to [20] .
Results
SIB1 FKBP22 and Its Mutants
A model for the three-dimensional structure of WT SIB1 FKBP22 and its domain organization was shown in Fig. 1a . The model was obtained from [6] which was built through a structural homology modelling. It displays a V-shaped dimeric structure of the WT where N-domain located on the base and C-domain at the tip of the V-shape. The design of SIB1 FKBP22 mutants was also shown in Fig. 1b , consisting of NNC-FKBP2, R37/L41R, N-domain and R142A mutants. NNC-FKBP22 was an engineered monomeric mutant that was constructed through artificial gly-gly-gly linker connecting two N-domains of SIB1 FKBP22. The design allowed N-and C-domains of NNC-FKBP22 folded similarly to the domains in WT-SIB1 FKBP22 [18] . Meanwhile, V37R/L41R mutant was constructed by disruption of Val-Leu zipper located at the dimer interface of N-domain. The disruption promoted unfolding of N-domain hence the mutant assumed in monomeric form [9] . N-domain mutant was constructed by removing C-domain of SIB1 FKBP22 as explained by [10] . This mutant is in dimeric form and contains α3-helix, which was proposed to be important for proper folding of the domain [10, 14] . Lastly, R142A structurally resembles WT SIB1 FKBP22 in which this mutant is in V-shaped dimeric form with folded N-and C-domains [9] . This mutant however exhibited lower PPIase activity as compared to WT SIB1 FKBP22 hence considered as one of active site mutant of SIB1 FKBP22 [9] . The use of monomeric, dimeric and active site mutants in this study is in light of addressing the structural regulation of SIB1 FKBP22 on ligand binding and substrate specificity.
Inhibition by FK506
Alignment of amino acid sequences indicated that SIB1 FKBP22 is undoubtedly a member of PPIase with conserved residues for catalytic activity and binding to FK506 (Fig. 2) . However, it remains to be experimentally evidenced to confirm if this protein is indeed a member of FKBP family proteins; binding to FK506 and substrate specificity, in particular. Figure 3 monomeric mutants of NNC-FKBP22, C-domain+ and V37R/L41R were 86.61, 96.03 and 81.57 nM, respectively, which were slightly higher yet comparable to that of WT SIB1 FKBP22 (Fig. 3) . By contrast, IC 50 of FK506 towards dimeric mutant of R142A was calculated to be 14.77 nM, which was significantly lower than that of WT SIB1 FKBP22. N-domain mutant was reported to have no catalytic activity [6] . Hence, the domain was not included in the FK506 inhibition measurement.
Substrate Specificity
Substrate specificity of SIB1 FKBP22 was measured using a tetrapeptide substrate containing different amino acid preceeding proline residue (Suc-Ala-Xaa-Pro-Pro-pNA). Xaa position refers to P1 position in the nomenclature for binding of peptide or protein substrate according (Fig. 4) . In this study, eleven (11) variants of the tetratepeptide substrates were used by replacing Xaa to Leu/Phe/Trp/Ala/Gln/Val/ Ile/His/Asp/Lys/Glu. All these residues have differences in polarity and structural bulkiness that might affect the fitting into the binding pocket. Figure 5 showed that hydrophobic residues preceding proline bond was more preferable for SIB1 FKBP22. Out of hydrophobic residues, Leu at Xaa position promoted the highest catalytic efficiency (k cat /K M ). Meanwhile, no activity, as well as FK506 inhibition, was detected when Glu was at Xaa site. In overall, the preference of SIB1 FKBP22 towards Xaa at P1 position followed the following order: Leu > Phe > Lys > Trp > Val > Ile > His > Asp > Ala > Gln > Glu. All monomeric mutants (NNC-FKBP22, C-domain+ and V37R/L41R mutant) exhibited similar substrate preferences as compared to dimer WT SIB1 FKBP22 (Fig. 5) . Noteworthy, preferences toward His and Asp were comparable in NNC-FKBP22 and C-domain+. Meanwhile, C-domain+ also showed comparable preferences toward Lys and Trp. By contrast, dimeric mutant R142A displayed slightly different substrate specificity (Fig. 5) , in which the mutant displayed significant higher activity towards Ala of Xaa than WT SIB1 FKBP22, while the activity towards Lys of Xaa was significantly decreased. In overall, substrate preferences of R142A followed the following sequence: Leu > Phe > Ala > Tr p > V al > Ile > Lys > Asp > G l n > Hi > Glu.
Inhibition of Phosphatase Activity of Calcineurin
The ability of SIB1 FKBP22 to inhibit phosphatase activity of calcineuri has never been studied. To confirm this, phosphatase activity of calcineurin was measured in the presence of variants SIB1 FKBP22: NNC-FKBP22, V37R/ L41R-FKBP22, N-domain and R142A mutants. Figure 6 showed that in the absence of FK506, WT SIB1 FKBP22 was able to slightly inhibit phosphatase activity of calcinuerin up to 80.86%. 4 Nomenclature for binding of a pep tid e o r pr otein su bst rat e to a P PIa se according to th e S chechter and Berger nomenclature for binding of a peptide substrate to a peptidase. The PPIase is represented by the shaded area. R is the side chain of Xaa amino acid. P2, P1, P1′, and P2′ are the amino acid residues of the substrate. S2, S1, S1′, and S2′ are the corresponding subsites on the enzyme (SIB1 FKBP22)
Fig. 5
Comparison of substrate specificity of WT SIB1 FKBP22 with its mutants. PPIase activity towards Phe as an Xaa residue in the substrate was adjusted to 100% activity included in the measurement due to no previous information on involvement of this domain to calcineurin.
Discussion
FK506 has been known to specifically bind and inhibit FKBP family proteins but not to two other PPIase groups: cyclophilin and parvulin. This compound is known as an immunosuppressive drug used mainly after allogeneic organ transplant to lower the risk of organ rejection [21] . Atomic structure of FK506-human FKBP12 indicated that FK506 binds to same binding pocket as peptide substrate of PPIase activity [22] . This implied that inhibition of FK506 is due to competitive binding between FK506 and peptide substrate to the pocket binding. The binding affinity of peptide substrate is believed to be much lower as compared to that of while FK506 bind in much stronger affinity (in nano molar range). IC 50 value of FK506 towards WT SIB1 FKBP22 observed in this study (77.55 nM) was higher than E. coli FKBP22 (25 nM) [20] , human FKBP16 (55 nM) [23] and Neurospora crassa FKBP13 (48 nM) [24] . SIB1 FKBP22 was more sensitive to macrolide FK506 than human FKBP25 (160 nM) [24] and L. pneumophila FKBP25 (220 nM) [25] . In addition, the value also indicated that SIB1 FKBP22 was about 200-fold less sensitive than human FKBP12 (0.40 nM) [26] . Despite the amino acid sequences for PPIase activity are highly conserved among all these FKBPs, yet the residues involved in the FK506 interaction is less conserved (Fig. 2) . This leads to differences on the binding to FK506 and might account for the discrepancy on binding affinity to FK506. Similar assumption was also previously proposed by [27] for the discrepancy of FK506 binding among FKBP members.
We have previously reported that monomeric mutants exhibited slightly higher PPIase activity to WT SIB1 FKBP22 [10, 11] . However, Fig. 3 demonstrated that all monomeric mutants have similar IC 50 value as compared to WT SIB1 FKBP22, in dimeric structure. We previously speculated that monomeric forms have more structural flexibility in ligand binding hence the PPIase activity of the monomeric variants is higher than dimeric forms of SIB1 FKP22 [11] . Dimeric forms might restrict the movement of C-catalytic domain, located at the tip of V-shaped dimeric structure of SIB1 FKBP22, in capturing the substrate. However, the current result indicated that binding of both monomeric and dimeric forms were similar. This implied that, in contrast to peptide substrate of PPIase activity, structural freedom of catalytic domain has no or, if any, little effect on the binding to FK506. This discrepancy might be due to much higher binding affinity of FK506 to C-catalytic domain as compared to peptide substrate.
Interestingly, mutation at residue located at the binding pocket (R142A mutant) was shown to decrease IC 50 value (Fig. 3) . The following reasons might be attributed to this finding. First, R142A mutant has higher binding affinity towards FK506 hence required less FK506 in order to inhibit its PPIase activity. Complex structure of human FKBP12-FK506 indicated that R142 interacted to CI5 methoxy of FK506 through hydrophobic interaction [28] . Mutation of Arg142 to Ala increased the hydrophobicity at this site and might affect the interaction to FK506. This result is different as compared to mutations at the corresponding residue at human FKBP12 (R42). Mutation at this residue to hydrophobic residue (R42L) has no significant effect on the binding to FK506. While mutation to Gln (R42Q) reduced the sensitivity towards FK506 by only 7-8-fold lower [29] . This might be due to differences in the residues surrounding this site at human FKBP12 and SIB1 FKBP22 thus the geometrical configurations of the binding pocket of both proteins are not the same.
Alternatively, lower IC 50 of R142A mutant might be due to lower PPIase activity of the mutant as compared to WT SIB1 FKBP22. Hence, lower concentration of FK506 is sufficient to inhibit 50% of PPIase activity of R142A mutant. Previously, we reported that R142A exhibited about 32% of WT activity [9] . This residue was proposed to be involved in PPIase activity in auxiliary manner, in which it maintains another active site (D137) at proper orientation for optimum catalysis through salt bridge formation. D137 further reduces a resonance effect of the peptide bond by directly forming a hydrogen bond with the peptide bond nitrogen. The fact of only active site mutant (R142A) showed considerably different IC 50 value, this indicated that FK506 binding is solely regulated by structural configuration at active site. Dimerization has no effect on binding to FK506 as explained above. Noteworthy, N-domain has no PPIase activity due to the lack of C-domain [10] . Accordingly, binding to FK506 was also not determined.
Further, substrate specificity result indicated that hydrophobic residues preceding proline bond was more preferable for SIB1 FKBP22. Out of hydrophobic residues, Leu at Xaa position promoted the highest catalytic efficiency (k cat /K M ). This finding demonstrated that SIB1 FKBP22 behaves as other member of FKBP family proteins in which bulky hydrophobic residues as a residue preceding the proline are preferred for maxium PPIase activity [5, 20] . Meanwhile, two other members of PPIase, cyclophilin and parvulin, displayed a different specificity for the Xaa position. Cyclophilin has wide specificity at Xaa position [30] , while Parvulin having a unique specificity for a phosphorylated Ser or Thr preceding the Pro [5, 30] . The discrepancy in the specificity among PPIase member is believed due to structural differences in substrate binding pocket that affect the fitting of each substrate [5] .
All monomeric variants exhibited similar substrate preferences as compared to dimer WT SIB1 FKBP22. This suggested that dimerization has no role on substrate specificity. Given the catalytic efficiency between monomeric and dimeric forms of SIB1 FKBP22 are different [6, 9, 11] , this also suggests that there is no structural relationship between catalytic efficiency and substrate specificity. Structural, catalytic efficiency might be more related to the flexibility of overall C-catalytic domain, located at the tip of V-shaped dimeric structure of SIB1 FKBP22, in capturing the substrate. Restriction of C-catalytic domain due to dimerization at the distal of N-domain might affect the rate of substrate binding to the domain which have been further catalyzed. Specificity was then speculated to be more related to local structural configuration at the active site.
To confirm, substrate specificity of active site mutant (R142A) was also determined (Fig. 5) . It is obvious that the mutation at pocket binding has some effects on the substrate specificity, in which that this protein was likely able to adapt bulkier hydrophobic residues at the binding pocket. When Phe was placed at Xaa site, the activity was comparable with Leu-substrate. In addition, catalytic efficiency of R142A mutant towards Trp-substrate was shown to be increased compared to that of WT. This suggested that binding pocket of R142A mutant was able to adopt aromatic chains of Phe or Trp. This might be due to increasing of hydrophobicity by introduction of Ala at Arg142 site and widening the substrate binding pocket. Besides, removal of Arg side chain by Ala mutation was believed to make the binding pocket getting wider thus able to accommodate bulkier chain. Nevertheless, removal of Arg caused Asp37 not in proper orientation for catalysis. It thus, in overall, the catalytic efficiency of R142A mutant to all substrate variants was lower as compared to WT.
Given SIB1 FKBP22 was shown to be able to bind to and catalytically inhibited by FK506, it is then interesting if a complex of SIB1 FKBP22-FK506 enables to inhibit phosphatase activity of calcineurin. It was previously reported that human FKBP12 has been shown to inhibit calcineurin in the presence of FK506, but not in the absence of FK506 [31] . Surprisingly, our result indicated that WT SIB1 FKBP22 and the mutants was able to slightly inhibit calcineurin in the absence of FK506. The inhibition was then extremely increased by the presence of FK506. Similar result was also found in human FKBP38 [32] and Plasmodium falciparum FKBP35 [19] . While human FKBP51 has also shown to bind to calcineurin in the absence of FK506, yet the inhibition of phosphatase activity was only observed when FK506 was added [33] . The discrepancy might be due to structural differences among these FKBP members. FKBP38 and FKBP35 are multidomain FKBPs consisting of a PPIase domain, or FKBP domain, followed by additional domain(s). It remains to be further investigated if non-PPIase domain could contribute to the interaction and inhibition of calcineurin. Besides, no study has so far been reported on the effect of oligomerization on the ability of FKBPs in the inhibition of phosphatase activity of calcineurin. Yet, [19] proposed that PPIase domain is the only domain involved in the interaction and inhibition of calcineurin. Similarly, our result also indicated that all mutants with the presence of C-domain, regardless of their oligomerization state, were able to inhibit phosphatase activity of calcineurin, in the absence or in the presence of FK506. This suggested that the presence of C-domain, responsible for PPIase activity, is essential for the inhibition. However, the inhibition activity of monomeric mutants (NNC-FKBP22, C-domain+, and V37R/L41R) was slightly lower than that of dimeric forms of WT. This indicated that dimeric forms contributed to maximize ability of SIB1 FKBP22 to bind and inhibit calcineurin. The role of dimeric structure in this event might similar in the previous proposal for V-shaped dimeric structure for efficient binding to protein substrate [11, 34] . This implied that optimum binding to calcinuerin, for further inhibition, was facilitated by V-shaped dimeric structure of SIB1 FKBP22. The binding might contribute to proper orientation of calcineurin toward C-domain of SIB1 FKBP22 to proceed the inhibition. This result also implied that non PPIase domain in FKBP family proteins might be involved in the binding to calcineurin for optimum inhibition. Involvement of non PPIase domain in the interaction with calcineurin was also reported in human FKBP51 [33] .
The importance of catalytic domain was confirmed by measuring inhibition ability of N-domain and R142A mutants towards phosphatase activity of calcineurin. N-domain displayed no inhibition activity towards calcineurin in the absence or in the presence of FK506. Meanwhile, R142A mutant exhibited the inhibition activity yet lower than WT. This implied that N-domain alone is not sufficient to inhibit calcineurin. This domain might interact to calcineurin, however the lack of C-domain caused inability to inhibit calcineurin. Alternatively, this suggested that the presence of C-domain is essential for the inhibition. Further, ability of R142A to inhibit calcineurin is also related to similarity on overall structure of R142A with WT FKBP22, in which the mutant is in dimeric structure with folded N-and C-domain, as confirmed with CD spectra [9] and differential scanning calorimetry (data not shown). However, the lower activity of this mutant as compared to WT conceivably due to lower affinity of FK506 that mediates the inhibition.
Altogether, this result clearly demonstrated that dimeric structure of SIB1 FKBP22 plays important role for any function of this protein towards protein substrate (calcineurin). The role of dimeric structure is fairly more on binding function, not catalysis. Meanwhile, C-domain is also believed not only play essential role in catalysis, but also for binding to small ligand that fits to the pocket binding. Thus, it was acceptable that there were no differences on FK506 binding and substrate specificity between dimeric and monomeric forms of SIB1 FKBP22. Interestingly, the importance role of C-domain in calcineurin inhibition might implied that this domain also interacts to a bigger substrate (protein/calcineurin). Indeed, human FKBP12, with no additional domain and same size as C-domain of SIB1 FKBP22, demonstrated the ability to inhibit calcinuerin.
The ability of SIB1 FKBP22 to inhibit calcineurin phosphatase activity could be exaggerated to cellular function of this protein inside SIB1 cells. This implied that SIB1 FKBP22 may not only be involved in protein folding event inside the cells, but also involved in phosphate-mediated signal transduction of SIB1 cells. Yet, up to date, calcineurin was only found in eukaryote kingdom [34] , hence SIB1 FKBP22 might bind to indigenous regulator that may function as calcineurin. Besides, interaction of SIB1 FKBP22 to interact to folded state calcineurin also confirmed our previous assumption that this protein is able to bind fully folded state of protein, not only a folding intermediate protein. Binding to a folding intermediate protein is attributed to character of SIB1 FKBP22 as a chaperone molecule. Meanwhile, the ability to bind to a fully folded protein is related to involvement of SIB1 FKBP22 in mediating protein-protein network for various cellular functions. Accordingly, SIB1 FKBP22 might be involved in wider cellular function of SIB1 cells than we ever thought before.
Conclusion
Most of studies for ligand binding and substrate specificity were so far limited to monomeric FKBPs family member. SIB1 FKBP22 is a cold-adapted dimeric FKBP consisting of N-dimerization and C-catalytic domain and having optimum PPIase activity at 10 °C. In this study, we demonstrated that catalytic activity of SIB1 FKBP22 was indeed inhibited by FK506, a common inhibitor for FKBPs family member. This inhibition was due to binding of this protein to FK506 which was shown to be only associated to local configuration at the active site, not by its dimeric structure. Meanwhile, substrate specificity of SIB1 FKBP22 was shown to follow others FKBPs family member, in which hydrophobic residues before proline substrate were preferable. Dimeric structure has no relation for the specificity, yet local configuration at the active site might change the specificity. This is the first report on structural regulation of ligand binding and substrate specificity for dimeric FKBPs family member. Lastly, FK506 binding of SIB1 FKBP22 was shown to be important for maximum inhibition activity of this protein towards calcineurin activity. It is interesting to be noted that the presence of C-domain is essential for the inhibition activity, meanwhile dimeric structure might be required for efficient binding to calcineurin protein substrate.
